Research progress in estrogen as an adjunctive therapy for schizophrenia.

Significant gender differences exist in schizophrenia across multiple clinical dimensions.

• Gender differences are observed in age of onset, clinical presentation, disease progression, treatment efficacy, and prognosis among patients with schizophrenia.
• These differences are largely attributed to variations in sex hormone levels.
• Estrogen has emerged as a key focus of research in explaining these gender-based differences.

Adjunctive estrogen therapy during schizophrenia treatment alleviates symptoms.

• Some studies suggest that adjunctive estrogen therapy not only alleviates symptoms but also reduces the required dosage of antipsychotic medications.
• This finding is based on a systematic review of existing research on estrogen as an adjunctive treatment for schizophrenia.
• The paper characterizes schizophrenia as a chronic psychiatric disorder with complex etiology and incompletely understood pathogenesis.

Adjunctive estrogen therapy may reduce the required dosage of antipsychotic medications in schizophrenia treatment.

• Studies suggest that adjunctive estrogen therapy can reduce the required dosage of antipsychotic medications.
• This potential dose-reducing effect is presented alongside symptom alleviation as a key benefit of estrogen adjunctive therapy.
• The review frames this finding as providing 'new perspectives and references for future therapeutic strategies' for schizophrenia.

Estrogen is identified as a key hormonal factor underlying sex-based differences in schizophrenia outcomes.

• Variations in sex hormone levels are described as largely responsible for gender differences in schizophrenia.
• Among sex hormones, estrogen is described as 'emerging as a key focus of research.'
• The paper positions estrogen research within the broader context of incompletely understood schizophrenia pathogenesis and triggering factors.